GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » ROIC %

Hemagen Diagnostics (Hemagen Diagnostics) ROIC % : -11.97% (As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Hemagen Diagnostics's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2012 was -11.97%.

As of today (2024-06-09), Hemagen Diagnostics's WACC % is 0.00%. Hemagen Diagnostics's ROIC % is 0.00% (calculated using TTM income statement data). Hemagen Diagnostics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Hemagen Diagnostics ROIC % Historical Data

The historical data trend for Hemagen Diagnostics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics ROIC % Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.17 -8.50 21.82 -21.94 -26.71

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.98 -56.73 -29.96 -3.03 -11.97

Competitive Comparison of Hemagen Diagnostics's ROIC %

For the Biotechnology subindustry, Hemagen Diagnostics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's ROIC % distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's ROIC % falls into.



Hemagen Diagnostics ROIC % Calculation

Hemagen Diagnostics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Sep. 2012 is calculated as:

ROIC % (A: Sep. 2012 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Sep. 2011 ) + Invested Capital (A: Sep. 2012 ))/ count )
=-0.438 * ( 1 - 0% )/( (1.855 + 1.425)/ 2 )
=-0.438/1.64
=-26.71 %

where

Hemagen Diagnostics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2012 is calculated as:

ROIC % (Q: Sep. 2012 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2012 ) + Invested Capital (Q: Sep. 2012 ))/ count )
=-0.176 * ( 1 - 0% )/( (1.515 + 1.425)/ 2 )
=-0.176/1.47
=-11.97 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2012) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemagen Diagnostics  (OTCPK:HMGN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Hemagen Diagnostics's WACC % is 0.00%. Hemagen Diagnostics's ROIC % is 0.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Hemagen Diagnostics ROIC % Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines